Asciminib Shows Clinical Activity for Pretreated CML in Phase 1 Trial
Asciminib appeared to have clinical activity in a population of heavily pretreated patients with chronic myeloid leukemia, including those with a T315I mutation.
Christina Bennett, MS
Christina Bennett, MS, is an independent medical journalist who writes about a variety of medical topics, including oncology, health care policy, and cell and gene therapies. She has a bachelor's degree in biomedical science and a master’s degree in science and technology journalism, both from Texas A&M University. She is a member of the Association of Healthcare Journalists and the National Association of Science Writers and was one of a dozen journalists selected for the 2017 National Cancer Reporting Fellowships.
